IP Library Granted Patent US 9,187,529
Granted Patent B2
US 9,187,529 · App. 14/367,116 · Granted Nov 17, 2015

Cationic peptides and use of such peptides for inhibiting exotoxin production

Inventor: Patrick M. Schlievert (Iowa City, IA)
Assignee: Regents of the University of Minnesota
C07K7/06A61K9/00A61L15/32A61L15/46A61L17/005A61L17/145A61L28/0023A61L28/0038A61L28/0069A61L29/048C07K14/195C07K14/4723A61F13/00063A61F13/8405A61K38/00A61L2300/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,529
App. No.
14/367,116
Granted
Nov 17, 2015
Kind
B2
Abstract

Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.

Claims (19)

1. An isolated peptide wherein said peptide is from 10 to 50 amino acids in length, and wherein the percentage of positively charged amino acids above the number of negatively charged amino acids is 15% or higher, and wherein the peptide comprises an amino acid as set forth in SEQ ID NO:5 or SEQ ID NO:6.

2. The peptide of claim 1 , wherein said peptide is from 18 to 30 amino acids in length.

3. The peptide of claim 1 , wherein the percentage of positively charged amino acids above the number of negatively charged amino acids is 18% or higher.

4. The peptide of claim 1 , wherein the percentage of positively charged amino acids above the number of negatively charged amino acids is 25% or higher.

5. The peptide of claim 1 , wherein the percentage of positively charged amino acids above the number of negatively charged amino acids is 50% or higher.

6. The peptide of claim 1 , wherein the percentage of positively charged amino acids above the number of negatively charged amino acids is 70% or higher.

7. The peptide of claim 1 , wherein said positively charged amino acids comprise one or more of lysine, a lysine analog, arginine, an arginine analog, histidine, or a histidine analog.

8. The peptide of claim 1 , wherein said peptide consists of the amino acid sequence SKPKKKKYKPHKKKSHKSAKKK (SEQ ID NO: 5) or SKPKKKTYKPHKDLSHGSAKKK (SEQ ID NO: 6).

9. A composition comprising one or more peptides and a pharmaceutically acceptable carrier, wherein each peptide is a peptide of claim 1 .

10. The composition of claim 9 , wherein said composition is formulated for subcutaneous administration.

11. The composition of claim 9 , wherein said composition is formulated for intramuscular administration.

12. The composition of claim 9 , wherein said composition is formulated for oral administration.

13. The composition of claim 9 , wherein said composition is formulated for topical administration.

14. The composition of claim 9 , wherein said composition is formulated for vaginal administration.

15. A composition comprising a medical or hygienic device and the peptide of claim 1 .

16. The composition of claim 15 , wherein all or part of the device is impregnated, or all or part of the surface of the device is coated, with the one or more peptides.

17. The composition of claim 15 , wherein said device is a vaginal tampon.

18. The composition of claim 15 , wherein said device is a surgical suture, a surgical bandage, a surgical dressing, or an osmotic pump.

19. The composition of claim 15 , wherein said device is an ostomy device.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2014
From: SCHLIEVERT, PATRICK M.
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 033967/0930 →
CONFIRMATORY LICENSE Recorded Sep 30, 2014
From: REGENTS OF THE UNIVERSITY OF MINNESOTA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033858/0845 →
Continuity (2)
Provisional Application 61578570 · Dec 21, 2011
Related Publication 20140356409A1 · Dec 4, 2014